The Safety and Efficiency of Sildenafil in the Treatment of Severe Post-capillary Pulmonary Hypertension Caused by COPD
The Safety and Efficiency of Sildenafil in the Treatment of Severe Post-capillary Pulmonary Hypertension Caused by COPD
Over half of chronic obstructive pulmonary disease (COPD) patients develop pulmonary
 hypertension. The current therapy focuses only on the basic disease and there are a lot of
 controversies about the use of PAH target therapy in group 3 pulmonary hypertension. Our
 study is to explore whether sildenafil, a pulmonary arterial hypertension (PAH) target drug,
 could be efficient and safe in improving symptoms and survival of severe pulmonary
 hypertension caused by COPD.
Inclusion Criteria:

 -  Stable for over 1 month

 -  mean pulmonary artery pressure ≥35mmHg, pulmonary wedge pressure≤ 15mmHg

 -  never received target therapy before

 Exclusion Criteria:

 -  Patients with other serious respiratory diseases

 -  Patients with pulmonary hypertension other than group 3

 -  Patients with right heart hypertrophy or dysfunction not caused by chronic obstructive
 pulmonary diseases

 -  Patients with limited life expectancy

 -  Patients with history of tracheal intubation or stoke, acute coronary syndrome in 6
 months

 -  Psychopath or addict

 -  Nonstable patients with type Ⅰor Ⅱ respiratory failure

 -  Patients with contraindication for sildenafil

 -  Patients in pregnancy or breastfeeding